Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

References for PMC Articles for PubMed (Select 20701602)

1.

NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism.

Yao Z, Xing L, Boyce BF.

J Clin Invest. 2009 Oct;119(10):3024-34. doi: 10.1172/JCI38716. Epub 2009 Sep 21.

2.

Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha.

Lu ZG, Liu H, Yamaguchi T, Miki Y, Yoshida K.

Cancer Res. 2009 Jul 15;69(14):5927-35. doi: 10.1158/0008-5472.CAN-08-4786. Epub 2009 Jun 23.

3.

Preventing oxidative stress: a new role for XBP1.

Liu Y, Adachi M, Zhao S, Hareyama M, Koong AC, Luo D, Rando TA, Imai K, Shinomura Y.

Cell Death Differ. 2009 Jun;16(6):847-57. doi: 10.1038/cdd.2009.14. Epub 2009 Feb 27.

4.

Modulation of DNA methylation by a sesquiterpene lactone parthenolide.

Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, Aimiuwu J, Pang J, Bhasin D, Neviani P, Fuchs JR, Plass C, Li PK, Li C, Huang TH, Wu LC, Rush L, Wang H, Perrotti D, Marcucci G, Chan KK.

J Pharmacol Exp Ther. 2009 May;329(2):505-14. doi: 10.1124/jpet.108.147934. Epub 2009 Feb 6.

5.

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.

Baud V, Karin M.

Nat Rev Drug Discov. 2009 Jan;8(1):33-40. doi: 10.1038/nrd2781. Review.

6.

The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.

Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C, Brennan P, Rowntree C, Pepper C.

Clin Cancer Res. 2008 Dec 15;14(24):8102-11. doi: 10.1158/1078-0432.CCR-08-1673.

7.

Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.

Jenkins C, Hewamana S, Gilkes A, Neelakantan S, Crooks P, Mills K, Pepper C, Burnett A.

Br J Haematol. 2008 Dec;143(5):661-71. doi: 10.1111/j.1365-2141.2008.07392.x.

PMID:
19036014
8.

Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.

Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G.

Apoptosis. 2008 Sep;13(9):1148-61. doi: 10.1007/s10495-008-0243-4.

PMID:
18670883
9.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH Jr, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M.

Blood. 2008 Aug 15;112(4):981-9. doi: 10.1182/blood-2007-10-115873. Epub 2008 May 21.

10.

Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.

Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, Catalano R, Pautasso M, Panuzzo C, Nicoli P, Messa E, Morotti A, Iacobucci I, Martinelli G, Bracco E, Saglio G.

Leukemia. 2008 Jun;22(6):1234-40. doi: 10.1038/leu.2008.68. Epub 2008 Apr 10. Retraction in: Leukemia. 2010 May;24(5):1103.

PMID:
18401421
11.

Antimyeloma effects of a sesquiterpene lactone parthenolide.

Suvannasankha A, Crean CD, Shanmugam R, Farag SS, Abonour R, Boswell HS, Nakshatri H.

Clin Cancer Res. 2008 Mar 15;14(6):1814-22. doi: 10.1158/1078-0432.CCR-07-1359.

12.

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.

Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C.

Blood. 2008 May 1;111(9):4681-9. doi: 10.1182/blood-2007-11-125278. Epub 2008 Jan 28.

13.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1060-6. Epub 2007 Oct 25.

14.

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT.

Blood. 2007 Dec 15;110(13):4427-35. Epub 2007 Sep 5.

15.
16.

Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL.

Cancer Cell. 2007 Jun;11(6):555-69.

17.

Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells.

Zunino SJ, Ducore JM, Storms DH.

Cancer Lett. 2007 Aug 28;254(1):119-27. Epub 2007 Apr 30.

PMID:
17470383
18.

Modeling the initiation and progression of human acute leukemia in mice.

Barabé F, Kennedy JA, Hope KJ, Dick JE.

Science. 2007 Apr 27;316(5824):600-4.

19.

Discovery and development of SAHA as an anticancer agent.

Marks PA.

Oncogene. 2007 Feb 26;26(9):1351-6. Review.

PMID:
17322921
20.

Vorinostat.

Grant S, Easley C, Kirkpatrick P.

Nat Rev Drug Discov. 2007 Jan;6(1):21-2. No abstract available.

PMID:
17269160
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk